A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease.

Background: In celiac disease, small intestinal transglutaminase 2 causes deamidation of glutamine residues in gluten peptides, which enhances stimulation of T cells and leads to mucosal injury. Inhibition of transglutaminase 2 is a potential treatment for celiac disease.

Methods: In a proof-of-concept trial, we assessed the efficacy and safety of a 6-week treatment with ZED1227, a selective oral transglutaminase 2 inhibitor, at three dose levels as compared with placebo, in adults with well-controlled celiac disease who underwent a daily gluten challenge.

Behavioral therapy is superior to follow-up without intervention in patients with supragastric belching-A randomized study.

Background: Behavioral therapy (BT) has been proven effective in the treatment of supragastric belching (SGB) in open studies. The aim was to compare BT to follow-up without intervention in patients with SGB in a randomized study.

Methods: Forty-two patients were randomized to receive 5 sessions of BT, comprising diaphragmatic breathing exercises, or to follow-up without intervention.

Randomised clinical trial: faecal microbiota transplantation versus autologous placebo administered via colonoscopy in irritable bowel syndrome.

Background: Irritable bowel syndrome (IBS) has been associated with microbial dysbiosis.

Aim: To investigate the efficacy of faecal microbiota transplantation (FMT) in the treatment of IBS.

Methods: Forty-nine IBS patients were randomised to receive autologous or allogenic FMT via colonoscopy.